IntrinsicIntrinsic
← All summaries

Arcutis Biotherapeutics, Inc.

ARQT
Financials & Chart →

Business Summary

Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs, leveraging a platform centered on validated biological targets and deep dermatology expertise . The company's core business model revolves around generating revenue from the sale of its approved topical and systemic treatments for immune-mediated dermatological conditions, primarily ZORYVE products, and from upfront license fees and milestone payments from strategic collaboration agreements . Primary customer segments include patients treated in dermatology offices, as well as those treated by primary care providers and pediatricians . The company estimates an actively prescription-treated patient market of approximately 17.0 million patients in the United States for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, with 8.4 million treated in dermatology offices and 8.6 million treated outside dermatology . Of those treated in dermatology offices, approximately 3.7 million are covered by Medicare or Medicaid, and 4.7 million by private payers .

The company's lead product, ZORYVE cream 0.3%, a once-daily topical roflumilast formulation, was initially launched in August 2022 for plaque psoriasis in individuals 12 years and older, with an expanded indication to 6 years and older in October 2023 . In November 2025, a supplemental New Drug Application (sNDA) was accepted for filing by the FDA to potentially expand this indication down to 2 years of age, with a PDUFA target action date of June 29, 2026 . ZORYVE cream 0.3% also received Health Canada approval in June 2023 for individuals 12 years and older, with an SNDS accepted in February 2026 for expansion down to 2 years old . ZORYVE foam 0.3% was approved by the FDA in December 2023 for seborrheic dermatitis in individuals aged 9 years and older, commercially launching in the United States in January 2024 and in Canada in December 2024 . In May 2025, ZORYVE foam received FDA approval for plaque psoriasis of the scalp and body in adults and adolescents 12 and older, launching in the United States in June 2025, and subsequently approved by Health Canada in October 2025 and launched in November 2025 . ZORYVE cream 0.15% was approved by the FDA in July 2024 for mild to moderate atopic dermatitis in adults and pediatric patients 6 years and older, launching commercially in the United States in July 2024 and in Canada in April 2025 . ZORYVE cream 0.05% was approved by the FDA and commercially launched in October 2025 for mild to moderate atopic dermatitis in children 2 to 5 years of age . The company also has ARQ-234, a fusion protein targeting the CD200 Receptor, in its pipeline for atopic dermatitis, with an Investigational New Drug application (IND) submitted in July 2025 and a Phase 1 study anticipated in the first quarter of 2026 .

For the fiscal year ended December 31, 2025, total product revenue, net, was $372.072 million , a significant increase from $166.542 million in the prior year . This was driven by ZORYVE cream 0.3% revenue of $120.995 million , ZORYVE foam revenue of $181.892 million , ZORYVE cream 0.15% revenue of $68.274 million , and ZORYVE cream 0.05% revenue of $911 thousand . Other revenue for the year was $4.0 million , derived from milestone payments under the Huadong License and Collaboration Agreement. Cost of sales increased by $17.6 million compared to the prior year, consistent with revenue growth and a $2.7 million increase in amortization expense related to AstraZeneca milestones . Research and development expenses slightly increased by $0.6 million, or 1%, to $77.051 million from $76.420 million in 2024 . Selling, general and administrative expenses rose by $45.2 million , primarily due to a $30.8 million increase in sales and marketing expenses and a $13.3 million increase in compensation and personnel-related expenses, reflecting continued commercialization efforts for ZORYVE . Interest income decreased by $7.2 million due to lower cash and marketable securities balances and reduced investment yields, while interest expense decreased by $15.1 million due to a $100.0 million principal paydown on the Loan Agreement in October 2024 and lower interest rates . The company reported a net loss of $16.1 million for the year ended December 31, 2025, a substantial improvement from a net loss of $140.0 million in 2024 . As of December 31, 2025, cash, cash equivalents, restricted cash, and marketable securities totaled $221.3 million , with an accumulated deficit of $1,138.1 million . Total outstanding debt under the Loan Agreement was $100.0 million .

Year-over-year, ZORYVE cream 0.3% product revenue, net, increased by $35.9 million, or 42% , driven by greater patient demand in the United States and Canada. ZORYVE foam product revenue, net, increased by $110.4 million, or 154% , primarily due to increased patient demand for seborrheic dermatitis in the United States, and the commercial launches for plaque psoriasis of the scalp and body in the United States (June 2025) and seborrheic dermatitis in Canada (December 2024). ZORYVE cream 0.15% product revenue, net, increased by $58.4 million, or 588% , largely due to its commercial launch in the United States in July 2024. ZORYVE cream 0.05% generated $0.9 million in revenue following its commercial launch in October 2025. Research and development expenses saw a modest 1% increase , with topical roflumilast program costs rising by $5.728 million, or 110% , due to the Phase 2 study for ZORYVE cream 0.05% in infants, while topical JAK inhibitor program costs decreased by $2.204 million, or 75% , following the completion of a Phase 1b study for ARQ-255. Other early stage programs also saw a decrease of $5.105 million, or 44% , primarily from reduced ARQ-234 preclinical and clinical manufacturing costs. Selling, general and administrative expenses increased by $45.2 million , reflecting expanded commercialization efforts.

During the reported period, Arcutis received FDA approval for ZORYVE foam for plaque psoriasis of the scalp and body in May 2025, and commercially launched it in the United States in June 2025 . Health Canada also approved ZORYVE foam for this indication in October 2025, with a commercial launch in November 2025 . ZORYVE cream 0.05% received FDA approval and was commercially launched in October 2025 for mild to moderate atopic dermatitis in children 2 to 5 years of age . In February 2026, positive topline data was announced for the INTEGUMENT-INFANT Phase 2 study of ZORYVE cream 0.05% in infants aged 3 months to less than 2 years with atopic dermatitis, with an sNDA submission planned for the second quarter of 2026 . The promotion agreement with Kowa Pharmaceuticals America, Inc. for ZORYVE in primary care and pediatrics, which began in late September 2024, was mutually terminated effective January 23, 2026 . The company made a $100.0 million partial prepayment on its Loan Agreement in October 2024 .

Business Outlook

Arcutis expects research and development expenses to increase in 2026, primarily driven by the clinical development program for ARQ-234 and ongoing ZORYVE label expansions and life cycle management efforts . The company anticipates that its existing capital resources, including cash, cash equivalents, and marketable securities of $221.3 million as of December 31, 2025 , will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of its financial statements .

A major growth area for Arcutis is the expansion of the ZORYVE franchise into additional indications through strategic lifecycle management, guided by over 40 published case reports and case series from clinicians using ZORYVE in various inflammatory dermatoses . The company plans to evaluate these potential signals of efficacy through resource-efficient Phase 2 proof-of-concept trials before selecting indications for Phase 3 pivotal trials, with initial diseases of interest including hidradenitis suppurativa and vitiligo . Another significant growth vector is the advancement of ARQ-234 through clinical development, which is a fusion protein and a potent and highly selective checkpoint agonist of the CD200 Receptor . ARQ-234 is planned for development in atopic dermatitis, where it is believed to be a highly complementary biologic treatment option to ZORYVE cream 0.15% . An Investigational New Drug application (IND) was submitted to the FDA in July 2025, and a Phase 1 study of ARQ-234 is anticipated to commence in the first quarter of 2026 . ARQ-234 also holds potential for treating multiple other inflammatory diseases, which the company may pursue internally or through partnerships .

Operationally, Arcutis expects selling, general and administrative expenses to increase in future periods as it continues to commercialize ZORYVE and potentially other product candidates, as well as support its operations . Following the termination of the promotion agreement with Kowa in January 2026, Arcutis plans to assume responsibility for sales and promotion of ZORYVE in the pediatric and primary care settings, initially with a small, targeted sales team focused on high-prescribing primary care and pediatric health care providers . The company does not own or operate any manufacturing facilities and relies on single-source third-party contract manufacturing organizations (CMOs) for nonclinical, clinical, and commercial supplies of ZORYVE and its product candidates . The company also uses additional contract manufacturers for labeling, packaging, and storage, and has secondary suppliers to ensure redundant supply for commercial products .

In terms of capital allocation, Arcutis made a $100.0 million partial prepayment on its Loan Agreement in October 2024 , reducing the outstanding principal to $100.0 million . In connection with this prepayment, the company is obligated to pay a prepayment penalty of $1.0 million by June 30, 2026 and a final fee of $6.95 million on January 1, 2027 . As a result of this prepayment, the company has the ability to draw down a tranche C-1 term loan of up to $50.0 million, expiring on March 31, 2026 , and a tranche C-2 term loan of up to $50.0 million, expiring on June 30, 2026 , subject to generating minimum net product revenue equal to 80% of projected net product revenue for the trailing six-month period prior to borrowing . The maturity date of the Loan Agreement is August 1, 2029 .

The company explicitly flags several structural headwinds and execution risks. The Inflation Reduction Act (IRA), enacted in 2022, requires manufacturers of certain drugs to engage in price negotiations with Medicare, imposes rebates for price increases exceeding inflation, and redesigns the Medicare Part D benefit . Arcutis was informed by CMS in April 2024 that it is not eligible for the phase-in of the manufacturer discount program under the IRA, which requires a 10% discount on Part D drugs in the initial coverage phase and a 20% discount in the catastrophic phase . The One Big Beautiful Bill Act, enacted in July 2025, imposes significant reductions in Medicaid program funding, which is expected to decrease enrollment and covered services, potentially adversely affecting ZORYVE sales in the Medicaid market . The current administration is pursuing a two-fold strategy to reduce drug costs, including potential tariffs on manufacturers not adopting most favored nation pricing and proposed regulations (Globe and Guard) in December 2025 that would implement mandatory payment models requiring rebates to the federal government based on most favored nation pricing . These policies are likely to negatively impact the pharmaceutical industry and may affect revenues for Arcutis's products and its ability to invest in clinical development .

Risk Factors

Arcutis faces several material risks, including significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications, which could lead to reduced market share and downward pressure on pricing . The company is currently involved in patent infringement litigation with Padagis Israel Pharmaceuticals Ltd. regarding a generic version of ZORYVE cream 0.3%, which could result in substantial costs and diversion of management attention, and if unsuccessful, could invalidate or narrow its patent claims . The automatic 30-month stay of FDA approval for Padagis's ANDA, initially set to expire on August 14, 2026, has been extended for each day the litigation stay is in place, starting March 24, 2025 . Macroeconomic factors, such as inflation, interest rates, political instability, conflicts, and trade disputes, could adversely affect business costs and overall financial performance . Cybersecurity threats, including sophisticated cyber-attacks and the use of AI by bad actors, pose a risk to the company's information technology systems and sensitive data, potentially leading to significant business disruption, data loss, and substantial remediation costs . Furthermore, the company's loan and security agreement with SLR Investment Corp. includes a financial covenant requiring minimum net product revenue equal to 75% of projected net product revenue, tested on a trailing six-month basis , with any failure to deliver an annual plan by December 15 of the prior year constituting an immediate event of default .

Management Priorities

Management emphasizes its strategy to leverage innovations in inflammation and immunology to identify molecules for validated biological targets in dermatology, aiming to develop and commercialize best-in-class products that address significant unmet needs in immuno-dermatology. The overall tone highlights a focus on growing the core ZORYVE business by establishing it as a foundational therapy for long-term management of plaque psoriasis, seborrheic dermatitis, and atopic dermatitis in both adults and children, with a particular emphasis on providing a therapeutic alternative to topical corticosteroids . Management also stresses the importance of expanding the prescribing base beyond dermatologists to primary care and pediatric health care providers, and continuing to expand insurance coverage, especially in Medicare and Medicaid . A key strategic priority is to expand the ZORYVE franchise into additional indications through strategic lifecycle management, utilizing clinical feedback and resource-efficient Phase 2 proof-of-concept trials for diseases like hidradenitis suppurativa and vitiligo . Another priority is to build the pipeline by advancing innovative medicines, with an initial focus on ARQ-234 for atopic dermatitis, for which a Phase 1 study is anticipated in the first quarter of 2026 .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 7, MD&A — Components of Our Results of Operations
  3. [3] Item 1, Business — Overview
  4. [4] Item 1, Business — Overview
  5. [5] Item 1, Business — Overview
  6. [6] Item 1, Business — Overview
  7. [7] Item 1, Business — Overview
  8. [8] Item 1, Business — Overview
  9. [9] Item 1, Business — Overview
  10. [10] Item 1, Business — Overview
  11. [11] Item 1, Business — Overview
  12. [12] Item 1, Business — Overview
  13. [13] Item 1, Business — Overview
  14. [14] Item 7, MD&A — Product Revenue, Net
  15. [15] Item 7, MD&A — Product Revenue, Net
  16. [16] Item 7, MD&A — Product Revenue, Net
  17. [17] Item 7, MD&A — Product Revenue, Net
  18. [18] Item 7, MD&A — Product Revenue, Net
  19. [19] Item 7, MD&A — Product Revenue, Net
  20. [20] Item 7, MD&A — Other Revenue
  21. [21] Item 7, MD&A — Cost of Sales
  22. [22] Item 7, MD&A — Cost of Sales
  23. [23] Item 7, MD&A — Research and Development Expenses
  24. [24] Item 7, MD&A — Research and Development Expenses
  25. [25] Item 7, MD&A — Selling, General and Administrative Expenses
  26. [26] Item 7, MD&A — Selling, General and Administrative Expenses
  27. [27] Item 7, MD&A — Interest Income
  28. [28] Item 7, MD&A — Interest Expense
  29. [29] Item 7, MD&A — Interest Expense
  30. [30] Item 1A, Risk Factors — Risks Related to Our Limited Operating History, Financial Condition, and Capital Requirements
  31. [31] Item 7, MD&A — Liquidity, Capital Resources and Requirements
  32. [32] Item 7, MD&A — Liquidity, Capital Resources and Requirements
  33. [33] Item 7, MD&A — Liquidity, Capital Resources and Requirements
  34. [34] Item 7, MD&A — Liquidity, Capital Resources and Requirements
  35. [35] Item 7, MD&A — Product Revenue, Net
  36. [36] Item 7, MD&A — Product Revenue, Net
  37. [37] Item 7, MD&A — Product Revenue, Net
  38. [38] Item 7, MD&A — Product Revenue, Net
  39. [39] Item 7, MD&A — Research and Development Expenses
  40. [40] Item 7, MD&A — Research and Development Expenses
  41. [41] Item 7, MD&A — Research and Development Expenses
  42. [42] Item 7, MD&A — Research and Development Expenses
  43. [43] Item 7, MD&A — Selling, General and Administrative Expenses
  44. [44] Item 1, Business — Overview
  45. [45] Item 1, Business — Overview
  46. [46] Item 1, Business — Overview
  47. [47] Item 1, Business — Overview
  48. [48] Item 1, Business — Overview
  49. [49] Item 7, MD&A — Liquidity, Capital Resources and Requirements
  50. [50] Item 7, MD&A — Research and Development Expenses
  51. [51] Item 7, MD&A — Liquidity, Capital Resources and Requirements
  52. [52] Item 7, MD&A — Liquidity, Capital Resources and Requirements
  53. [53] Item 1, Business — ZORYVE Indication Expansion
  54. [54] Item 1, Business — ZORYVE Indication Expansion
  55. [55] Item 1, Business — ARQ-234
  56. [56] Item 1, Business — ARQ-234
  57. [57] Item 1, Business — ARQ-234
  58. [58] Item 1, Business — Our Strategy
  59. [59] Item 7, MD&A — Selling, General and Administrative Expenses
  60. [60] Item 1, Business — Commercial Operations
  61. [61] Item 1, Business — Manufacturing & Supply
  62. [62] Item 1, Business — Manufacturing & Supply
  63. [63] Item 7, MD&A — Indebtedness
  64. [64] Item 7, MD&A — Indebtedness
  65. [65] Item 7, MD&A — Indebtedness
  66. [66] Item 7, MD&A — Indebtedness
  67. [67] Item 7, MD&A — Indebtedness
  68. [68] Item 7, MD&A — Indebtedness
  69. [69] Item 7, MD&A — Indebtedness
  70. [70] Item 7, MD&A — Indebtedness
  71. [71] Item 1A, Risk Factors — Recently enacted and future legislation and regulation may increase the difficulty and cost for us to commercialize ZORYVE and to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  72. [72] Item 1A, Risk Factors — Recently enacted and future legislation and regulation may increase the difficulty and cost for us to commercialize ZORYVE and to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  73. [73] Item 1A, Risk Factors — Recently enacted and future legislation and regulation may increase the difficulty and cost for us to commercialize ZORYVE and to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  74. [74] Item 1A, Risk Factors — Recently enacted and future legislation and regulation may increase the difficulty and cost for us to commercialize ZORYVE and to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  75. [75] Item 1A, Risk Factors — Recently enacted and future legislation and regulation may increase the difficulty and cost for us to commercialize ZORYVE and to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  76. [76] Item 1A, Risk Factors — We face significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications, and our operating results will suffer if we fail to compete effectively.
  77. [77] Item 1A, Risk Factors — The validity, scope, and enforceability of any patents listed in the Orange Book that cover ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE Cream 0.05%, or ZORYVE foam can be challenged by competitors.
  78. [78] Item 1A, Risk Factors — The validity, scope, and enforceability of any patents listed in the Orange Book that cover ZORYVE cream 0.3%, ZORYVE cream 0.15%, ZORYVE Cream 0.05%, or ZORYVE foam can be challenged by competitors.
  79. [79] Item 1A, Risk Factors — Macroeconomic factors, including unfavorable or uncertain global and regional economic, political and health conditions, could adversely affect our business, financial condition or results of operations.
  80. [80] Item 1A, Risk Factors — We depend on our information technology systems, and any failure of these systems, including due to the use of artificial intelligence (AI), or those of our CROs or other contractors or consultants we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations, financial condition, and prospects.
  81. [81] Item 1A, Risk Factors — The terms of our loan and security agreement require us to meet certain operating and financial covenants, and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
  82. [82] Item 1A, Risk Factors — The terms of our loan and security agreement require us to meet certain operating and financial covenants, and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
  83. [83] Item 1, Business — Our Strategy
  84. [84] Item 1, Business — Our Strategy
  85. [85] Item 1, Business — Our Strategy
  86. [86] Item 1, Business — Our Strategy

Analysis on 5/22/2026